Antiphospholipid syndrome in cardiovascular disease and cancer

Antiphospholipid syndrome is an autoimmune disorder which is characterized by the presence of heterogeneous antiphospholipid antibodies. There is an evidence on antiphospholipid (aPL) antibodies related to thromboembolic events in cancer patients. In fact, the thrombotic complications in patients wi...

Full description

Saved in:
Bibliographic Details
Published in:European journal of haematology 2023-12, Vol.111 (6), p.834-843
Main Authors: Pessach, Ilias, Kyriakou, Elias, Kalampokas, Emmanouil, Kalampokas, Theodoros, Bitsani, Aikaterini, Kotsianidis, Ioannis
Format: Article
Language:English
Subjects:
Antiphospholipid antibodies
Antiphospholipid syndrome
Cancer
Cardiovascular diseases
Clinical trials
Literature reviews
Malignancy
Risk factors
Thromboembolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antiphospholipid syndrome is an autoimmune disorder which is characterized by the presence of heterogeneous antiphospholipid antibodies. There is an evidence on antiphospholipid (aPL) antibodies related to thromboembolic events in cancer patients. In fact, the thrombotic complications in patients with malignancy occur at a rather high frequency, compared to other risk factors. In parallel with standard therapies available, there is need of case‐by‐case monitoring of each patient and the introduction of new therapies and need for more clinical trials which will address many questions for the optimal management of patients. This paper presents a basic review of the literature on the aPL antibodies associated with cardiovascular disease and cancer, as well as its complications, which are reported so far in the bibliography.
ISSN:0902-4441
1600-0609
DOI:10.1111/ejh.14096